Lansoprazole Tablet, Orally Disintegrating, Delayed Release
Product Images NDC 65862-896

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 65862-896). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Lansoprazole Fig1)

This is a graph with three lines representing the average severity of heartburn experienced by patients, measured on a scale of 0 (none) to 3 (severe), over time (in days) for three different groups: a placebo group, a group taking 15 mg of lansoprazole once a day, and a group taking 30 mg of lansoprazole once a day. The x-axis represents the days from the start of treatment and the y-axis represents the severity of heartburn.*

FDA Label Image

Figure2 (Lansoprazole Fig2)

The text provides a graph showing the mean severity of night heartburn by study day for evaluable patients. The severity is measured on a scale of 0 to 3, with 0 representing no heartburn and 3 representing severe heartburn. Three treatment groups are shown: placebo, lansoprazole 16 mg QD, and lansoprazole 30 mg QD. The x-axis shows the days from the start of treatment.*

FDA Label Image

Package Label-principal Display Panel (15 mg Blister Carton 100 (10 x 10) Unit-dose Tablets)

FDA Label Image

Package Label-principal Display Panel (30 mg Blister Carton 100 (10 x 10) Unit-dose Tablets)

This is a medication guide for Lansoprazole Delayed-Release Orally Disintegrating Tablets manufactured by Aurobindo. It contains instructions for use and administration. The tablets should not be chewed and can be swallowed with or without water. An alternative method of administration is through ralsyinge for children or patients with difficulty swallowing. The medication guide also includes information on storage and child-resistant packaging. The tablets contain 30 g of Lansoprazole USP and are not suitable for people with phenylketonuria. Printed medication guides can be found on the Aurobindo website.*

FDA Label Image

Chemical Structure (Lansoprazole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.